Mechanism of Action
Bombesin Receptor Subtypes
Bombesin activates three G-protein-coupled receptor subtypes. BB1 (NMB-R) mediates thermoregulation and feeding behavior. BB2 (GRP-R) regulates GI smooth muscle contraction, pancreatic enzyme secretion, and gastrin release from antral G-cells. BB3 has roles in energy homeostasis and insulin secretion. All three couple to Gq proteins, activating PLC, IP3, and intracellular calcium signaling.
Satiety and Appetite Suppression
Central and peripheral bombesin administration produces potent, dose-dependent satiety in animal models. BB2 receptor signaling in the hypothalamus and vagal afferents integrates gastrointestinal fullness signals with central appetite circuits. Unlike many satiety peptides, bombesin effects do not appear to require leptin/" class="wiki-internal-link">leptin signaling, suggesting utility even in leptin-resistant states.
Research Summary
Appetite and Obesity Research
AnimalBombesin reliably suppresses food intake in rodents and non-human primates through both peripheral GI and central hypothalamic actions. The mechanisms differ from GLP-1 agonists, suggesting potential for combination approaches in obesity treatment. BB3 agonists are currently in preclinical development as anti-obesity agents.
Cancer Imaging (Radiolabeled Analogs)
HumanGRP receptor overexpression in prostate, breast, pancreatic, and lung cancers makes bombesin analogs valuable as radiolabeled imaging agents. Multiple 68Ga-DOTA-bombesin and 177Lu-DOTA-bombesin analogs have entered clinical trials for PET imaging and targeted radionuclide therapy, showing high tumor specificity.
GI Function
AnimalBombesin stimulates gastric acid secretion, gallbladder contraction, and pancreatic enzyme release through peripheral GRP-R activation. These effects position bombesin analogs as potential therapeutic tools for conditions involving impaired GI secretory function.
Calculate your Bombesin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Appetite suppression | 10-100 nmol/kg | Pre-meal injection | Subcutaneous or IP |
| GI secretion studies | 5-50 nmol/kg | Single dose | IV or SC |
Research protocols are from animal models. Clinical applications are primarily radiolabeled analogs for oncology imaging.
Interactions
Safety Profile
At doses producing appetite suppression in animals, bombesin causes nausea-like behavior in some models, suggesting GI side effects at higher doses. Short half-life limits duration of any adverse effects. Radiolabeled bombesin analogs used clinically in oncology imaging have acceptable safety profiles. Bombesin itself has not been studied systematically in human appetite control trials.
References
- [1]Anastasi A, et al. Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the European amphibians Bombina bombina and Alytes obstetricans. Experientia. 1971.
- [2]Gibbs J, et al. Bombesin suppresses feeding in rats. Nature. 1979;282(5735):208-210.
- [3]Cornelio DB, et al. The gastrin-releasing peptide receptor as a molecular target in cancer. Front Endocrinol. 2016.